Latest news
Jazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication - MedscapeMedscape · Fri, 07 Aug 2026 08:24:31 GMTPharma Mar Flags Planned Loss of Zepzelca Second-Line SCLC Indication - TipRanksTipRanks · Thu, 06 Aug 2026 02:43:29 GMTFDA Names Zocilurtatug Pelitecan Orphan Drug in Neuroendocrine Carcinomas - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 16:09:36 GMTLurbinectedin Second-Line SCLC Indication to Be Withdrawn After LAGOON - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 14:09:27 GMTWithdrawal Planned for Second-Line Lurbinectedin in SCLC Indication - CancerNetworkCancerNetwork · Wed, 05 Aug 2026 14:09:23 GMTRecon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca - RAPSRAPS · Tue, 04 Aug 2026 20:19:00 GMTJazz to withdraw Zepzelca with FDA in second-line small cell lung cancer - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 13:18:16 GMTJazz Pharmaceuticals posts record $1.21B Q2 revenue, raises 2026 guidance - TradingViewTradingView · Mon, 03 Aug 2026 20:13:01 GMT